Research Article

You have full text access to this OnlineOpen article

Development of spontaneous multisystem autoimmune disease and hypersensitivity to antibody-induced inflammation in Fcγ receptor IIa–transgenic mice

  1. Caroline Tan Sardjono1,
  2. Patricia L. Mottram1,†,
  3. Nicholas C. van de Velde1,
  4. Maree S. Powell1,†,
  5. David Power1,
  6. Ronald F. Slocombe2,
  7. Ian P. Wicks3,
  8. Ian K. Campbell3,
  9. Steven E. McKenzie4,†,
  10. Mark Brooks5,
  11. Andrew W. Stevenson6,
  12. P. Mark Hogarth1,†,*

Article first published online: 30 SEP 2005

DOI: 10.1002/art.21344

Issue

Arthritis & Rheumatism

Arthritis & Rheumatism

Volume 52, Issue 10, pages 3220–3229, October 2005

Additional Information

How to Cite

Sardjono, C. T., Mottram, P. L., Velde, N. C. v. d., Powell, M. S., Power, D., Slocombe, R. F., Wicks, I. P., Campbell, I. K., McKenzie, S. E., Brooks, M., Stevenson, A. W. and Hogarth, P. M. (2005), Development of spontaneous multisystem autoimmune disease and hypersensitivity to antibody-induced inflammation in Fcγ receptor IIa–transgenic mice. Arthritis & Rheumatism, 52: 3220–3229. doi: 10.1002/art.21344

Author Information

  1. 1

    Austin Research Institute, Heidelberg, Victoria, Australia

  2. 2

    University of Melbourne, Melbourne, Victoria, Australia

  3. 3

    Walter and Eliza Hall Institute, Parkville, Victoria, Australia

  4. 4

    Jefferson Medical College, Philadelphia, Pennsylvania

  5. 5

    Austin Hospital, Heidelberg, Victoria, Australia

  6. 6

    Commonwealth Scientific Industrial Research Organization, Clayton South, Victoria, Australia

  1. †

    Drs. Mottram, Powell, and Hogarth have stock options in PrimaBiomed. Dr. McKenzie has received consulting fees (less than $10,000 per year) from GlaxoSmithKline.

*Helen McPherson-Smith Laboratory, Austin Research Institute, Studley Road, Heidelberg, Victoria 3084, Australia

  1. †

    Drs. Mottram, Powell, and Hogarth have stock options in PrimaBiomed. Dr. McKenzie has received consulting fees (less than $10,000 per year) from GlaxoSmithKline.

Publication History

  1. Issue published online: 30 SEP 2005
  2. Article first published online: 30 SEP 2005
  3. Manuscript Accepted: 30 JUN 2005
  4. Manuscript Received: 24 SEP 2004

Funded by

  • National Health and Medical Research Council
  • PrimaBiomed Ltd., Australia
  • PaperlinX Pty Ltd.
  • Nancy Prendergast fellowships from the Arthritis Foundation, Australia

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (266K)

REFERENCES

  • 1
    Dijstelbloem HM, Bijl M, Fijnheer R, Scheepers RH, Oost WW, Jansson MD, et al. Fcγ receptor polymorphisms in systemic lupus erythematosus: association with disease and in vivo clearance of immune complexes. Arthritis Rheum 2000; 43: 2793–800.
    Direct Link:
  • 2
    Takai T. Roles of Fc receptors in autoimmunity. Nat Rev Immunol 2002; 2: 580–92.
  • 3
    Ierino FL, Powell MS, McKenzie IF, Hogarth PM. Recombinant soluble human FcγRII: production, characterization, and inhibition of the Arthus reaction. J Exp Med 1993; 178: 1617–28.
  • 4
    Ravetch JV, Bolland S. IgG Fc receptors [review]. Annu Rev Immunol 2001; 19: 275–90.
  • 5
    De Stahl TD, Andren M, Martinsson P, Verbeek JS, Kleinau S. Expression of FcγRIII is required for development of collagen-induced arthritis. Eur J Immunol 2002; 32: 2915–22.
    Direct Link:
  • 6
    Ji H, Ohmura K, Mahmood U, Lee DM, Hofhuis FM, Boackle SA, et al. Arthritis critically dependent on innate immune system players. Immunity 2002; 16: 157–68.
  • 7
    Van Lent PL, Nabbe K, Blom AB, Holthusyen AE, Sloetjes A, van de Putte LB, et al. Role of activatory FcγRI and Fcγ III and inhibitory FcγRII in inflammation and cartilage destruction during experimental antigen-induced arthritis. Am J Pathol 2001; 159: 2309–20.
  • 8
    Hogarth PM. Fc receptors are major mediators of antibody based inflammation in autoimmunity [review]. Curr Opin Immunol 2002; 14: 798–202.
  • 9
    Powell MS, Barton PA, Emmanouilidis D, Wines BD, Neumann GM, Peitersz GA, et al. Biochemical analysis and crystallisation of FcγRIIa, the low affinity receptor for IgG. Immunol Lett 1999; 68: 17–23.
  • 10
    Chuang FY, Sassaroli M, Unkeless JC. Convergence of Fcγ receptor IIA and Fcγ receptor IIB signalling pathways in human neutrophils. J Immunol 2000; 164: 350–60.
  • 11
    Tan Sardjono C, Mottram PL, Hogarth PM. The role of FcγRIIa as an inflammatory mediator in rheumatoid arthritis and systemic lupus erythematosus [review]. Immunol Cell Biol 2003; 81: 374–81.
    Direct Link:
  • 12
    Maxwell KF, Powell MS, Hulett MD, Barton PA, McKenzie IF, Garrett TP, et al. Crystal structure of the human leukocyte Fc receptor, FcγRIIa. Nat Struct Biol 1999; 6: 437–42.
  • 13
    Powell MS, Hogarth PM. The role and use of recombinant receptors in the investigation and control of antibody-induced inflammation. In: van de WinkelJG, HogarthPM, editors. Immunoglobulin receptors and their physiological and pathological roles in immunity. Dordrecht (The Netherlands): Kluwer Academic Publishers; 1998.
  • 14
    Hulett MD, Hogarth PM. Molecular basis of Fc receptor function [review]. Adv Immunol 1994; 57: 1–127.
  • 15
    Daeron M. Fc receptor biology [review]. Annu Rev Immunol 1997; 15: 203–34.
  • 16
    McKenzie SE. Humanized mouse models of FcR clearance in immune platelet disorders [review]. Blood Rev 2002; 16: 3–5.
  • 17
    McKenzie SE, Taylor SM, Malladi P, Yuhan H, Cassel DL, Chien P, et al. The role of the human Fc receptor FcγRIIA in the immune clearance of platelets: a transgenic mouse model. J Immunol 1999; 162: 4311–8.
  • 18
    Manger K, Repp R, Spriewald BM, Rascu A, Geiger A, Wassmuth R, et al. Fcγ receptor IIa polymorphism in Caucasian patients with systemic lupus erythematosus: association with clinical symptoms. Arthritis Rheum 1998; 41: 1181–9.
    Direct Link:
  • 19
    Campbell IK, Hamilton JA, Wicks IP. Collagen-induced arthritis in C57BL/6 (H-2b) mice: new insights into an important disease model of rheumatoid arthritis. Eur J Immunol 2000; 30: 1568–75.
    Direct Link:
  • 20
    Svensson L, Nandakumar KS, Johansson A, Jansson L, Holmdahl R. IL-4-deficient mice develop less acute but more chronic relapsing collagen-induced arthritis. Eur J Immunol 2002; 32: 2944–53.
    Direct Link:
  • 21
    Barnes N, Gavin AL, Tan PS, Mottram P, Koentgen F, Hogarth PM. FcγRI-deficient mice show multiple alterations to inflammatory and immune responses. Immunity 2002; 16: 379–89.
  • 22
    Tan PS, Gavin AL, Barnes N, Sears DW, Vremec D, Shortman K, et al. Unique monoclonal antibodies define expression of FcγRI on macrophages and mast cell lines and demonstrate heterogeneity among subcutaneous and other dendritic cells. J Immunol 2003; 170: 2549–56.
  • 23
    Wilkins S, Gureyev T, Gao D, Pogany A, Stevenson A. Phase-contrast imaging using polychromatic hard X-rays. Nature 1996; 384: 335–8.
  • 24
    Courtenay JS, Dallman MJ, Dayan AD, Martin A, Mosedale B. Immunisation against heterologous type II collagen induces arthritis in mice. Nature 1980; 283: 666–8.
  • 25
    Matsumoto T, Ametani A, Hachimura S, Iwaya A, Taguchi Y, Fujita K, et al. Intranasal administration of denatured type II collagen and its fragments can delay the onset of collagen-induced arthritis. Clin Immunol Immunopathol 1998; 88: 70–9.
  • 26
    Butler DM, Malfait AM, Mason LJ, Warden PJ, Kollias G, Maini RN, et al. DBA/1 mice expressing the human TNF-α transgene develop a severe, erosive arthritis: characterization of the cytokine cascade and cellular composition. J Immunol 1997; 159: 2867–76.
  • 27
    Feldmann M. Development of anti-TNF therapy for rheumatoid arthritis. Nat Rev Immunol 2002; 2: 364–71.
  • 28
    Nandakumar KS, Svensson L, Holmdahl R. Collagen type II-specific monoclonal antibody-induced arthritis in mice: description of the disease and the influence of age, sex, and genes. Am J Pathol 2003; 163: 1827–37.
  • 29
    Cosgrove L. Monoclonal antibodies to platelet antigens. Melbourne (Australia): University of Melbourne; 1987.
  • 30
    Myers LK, Rosloniec EF, Cremer MA, Kang AH. Collagen-induced arthritis, an animal model of autoimmunity [review]. Life Sci 1997; 61: 1861–78.
  • 31
    Andersson EC, Hansen BE, Jacobsen H, Madsen LS, Andersen CB, Engberg J, et al. Definition of MHC and T cell receptor contacts in the HLA-DR4 restricted immunodominant epitope in type II collagen and characterization of collagen-induced arthritis in HLA-DR4 and human CD4 transgenic mice. Proc Natl Acad Sci U S A 1998; 95: 7574–9.
  • 32
    Nandakumar KS, Andren M, Martinsson P, Bajtner E, Hellstrom S, Holmdahl R, et al. Induction of arthritis by single monoclonal IgG anti-collagen type II antibodies and enhancement of arthritis in mice lacking inhibitory FcγRIIB. Eur J Immunol 2003; 33: 2269–77.
    Direct Link:
  • 33
    Feldmann M, Maini RN. Anti-TNFα therapy of rheumatoid arthritis: what have we learned? [review]. Annu Rev Immunol 2001; 19: 163–96.
  • 34
    Hahn B. Systemic lupus erythematosus and related syndromes. In: RuddyS, HarrisE, SledgeB, editors. Kelley's textbook of rheumatology. 6th ed. Philadelphia: W. B. Saunders; 2001. p. 1089–103.
  • 35
    Quattrocchi E, Dallman MJ, Feldmann M. Adenovirus-mediated gene transfer of CTLA-4Ig fusion protein in the suppression of experimental autoimmune arthritis. Arthritis Rheum 2000; 43: 1688–97.
    Direct Link:
  • 36
    Yuasa T, Kubo S, Yoshino T, Ujike A, Matsumura K, Ono M, et al. Deletion of Fcγ receptor IIB renders H-2b mice susceptible to collagen-induced arthritis. J Exp Med 1999; 189: 187–94.
  • 37
    Watson WC, Townes AS. Genetic susceptibility to murine collagen II autoimmune arthritis: proposed relationship to the IgG2 autoantibody subclass response, complement C5, major histocompatibility complex (MHC) and non-MHC loci. J Exp Med 1985; 162: 1878–91.
  • 38
    Clynes R, Maizes JS, Guinamard R, Ono M, Takai T, Ravetch JV. Modulation of immune complex-induced inflammation in vivo by the coordinate expression of activation and inhibitory Fc receptors. J Exp Med 1999; 189: 179–85.
  • 39
    Bolland S, Yim YS, Tus K, Wakeland EK, Ravetch JV. Genetic modifiers of systemic lupus erythematosus in FcγRIIB−/− mice. J Exp Med 2002; 195: 1167–74.
  • 40
    Bolland S, Ravetch JV. Spontaneous autoimmune disease in FcγRIIB-deficient mice results from strain-specific epistasis. Immunity 2000; 13: 277–85.
  • 41
    Daeron M. Structural bases of FcγR functions [review]. Int Rev Immunol 1997; 16: 1–27.
  • 42
    Allen JM, Seed B. Isolation and expression of functional high-affinity Fc receptor complementary DNAs. Science 1989; 243: 378–81.
  • 43
    Firestein GS. Etiology and pathogenesis of rheumatoid arthritis. 6th ed. Philadelphia: W. B. Saunders; 2001.
  • 44
    Feldmann M, Maini RN, Bondeson J, Taylor P, Foxwell BM, Brennan FM. Cytokine blockade in rheumatoid arthritis [review]. Adv Exp Med Biol 2001; 490: 119–27.
  • 45
    Moore J, Ma D, Will R, Cannell P, Handel M, Milliken S. A phase II study of rituximab in rheumatoid arthritis patients with recurrent disease following haematopoietic stem cell transplantation. Bone Marrow Transplant 2004; 34: 241–7.
  • 46
    Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004; 350: 2572–81.
  • 47
    Nordling C, Karlsson-Parra A, Jansson L, Holmdahl R, Klareskog L. Characterization of a spontaneously occurring arthritis in male DBA/1 mice. Arthritis Rheum 1992; 35: 717–22.
    Direct Link:
  • 48
    Hata H, Sakaguchi N, Yoshitomi H, Iwakura Y, Sekikawa K, Azuma Y, et al. Distinct contribution of IL-6, TNF-α, IL-1, and IL-10 to T cell-mediated spontaneous autoimmune arthritis in mice. J Clin Invest 2004; 114: 582–8.
  • 49
    Iwakura Y. Roles of IL-1 in the development of rheumatoid arthritis: consideration from mouse models [review]. Cytokine Growth Factor Rev 2002; 13: 341–55.
View Full Article (HTML) Get PDF (266K)